Titration of Cebranopadol
AssigneePark Therapeutics, Inc.
InventorsShaonan Wang, Chiara Piana, Roberta Bursi
Life of this patent
Estimating the term…
Abstract
The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval; and (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval; wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.
Claims50
A method of treating pain in a patient in need of such treatment, said method comprising administering Cebranopadol according to an administration regimen comprising:
- (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval, wherein the first daily dose of Cebranopadol is in an amount that is expected to be subtherapeutic for the patient;
- (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval;
- and
- (iii) a third administration interval, which lasts for at least 2 consecutive days and directly follows the second administration interval without interruption, wherein a third daily dose of Cebranopadol is administered on every day of the third administration interval;
- wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol;
- and
- wherein the second daily dose of Cebranopadol is lower than the third daily dose of Cebranopadol.
A method of reducing side effects associated with treatment for pain, said method comprising administering Cebranopadol according to an administration regimen comprising:
- (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval, wherein the first daily dose of Cebranopadol is in an amount that is expected to be subtherapeutic for the patient;
- (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval;
- and
- (iii) an optional third administration interval, which lasts for at least 2 consecutive days and directly follows the second administration interval without interruption, wherein a third daily dose of Cebranopadol is administered on every day of the third administration interval;
- wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol;
- and
- wherein the second daily dose of Cebranopadol is lower than the optional third daily dose of Cebranopadol.
A method of reducing side effects associated with treatment for pain, said method comprising administering Cebranopadol according to an administration regimen comprising:
- (i) a first administration interval, which lasts for at least 4 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval;
- (ii) a second administration interval, which lasts for at least 4 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval;
- and
- (iii) an optional third administration interval, which lasts for at least 4 consecutive days and directly follows the second administration interval without interruption, wherein a third daily dose of Cebranopadol is administered on every day of the third administration interval;
- wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol;
- and
- wherein the second daily dose of Cebranopadol is lower than the optional third daily dose of Cebranopadol.
Dependencies are inferred from the claim text.